L3VLUP
ProSign in

MRVI · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MRVILLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MRVI
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterMRVILLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 202011 holders, $410m29 holders, $17.3bn
Q1 20214 holders, $230m24 holders, $23.0bn
Q2 20218 holders, $819m24 holders, $27.8bn
Q3 202110 holders, $1.4bn31 holders, $29.9bn
Q4 20216 holders, $900m31 holders, $34.7bn
Q1 20224 holders, $342m24 holders, $35.3bn
Q2 20224 holders, $447m33 holders, $42.7bn
Q3 20227 holders, $527m31 holders, $43.4bn
Q4 20228 holders, $360m31 holders, $46.6bn
Q1 20238 holders, $291m33 holders, $44.3bn
Q2 20237 holders, $234m37 holders, $59.6bn
Q3 20236 holders, $155m44 holders, $67.6bn
Q4 20233 holders, $73m45 holders, $73.6bn
Q1 20245 holders, $110m41 holders, $95.3bn
Q2 20246 holders, $91m43 holders, $110bn
Q3 20241 holders, $34m45 holders, $107bn
Q4 20241 holders, $251k46 holders, $93.9bn
Q1 2025none listed holders, n.a.42 holders, $98.4bn
Q2 2025none listed holders, n.a.43 holders, $93.2bn
Q3 20251 holders, $1.3m39 holders, $86.7bn
Q4 20251 holders, $5.8m41 holders, $123bn
Q1 20261 holders, $7.1m39 holders, $106bn
Q2 20262 holders, $24m44 holders, $132bn
MRVI

Maravai Lifesciences HLDGS I

Holders
1
Reported value
$34m
Buyers
1
Sellers
1

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
45
Reported value
$107bn
Buyers
24
Sellers
22

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MRVI (0)

None.

Only LLY (44)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, and 19 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →